Topical gels for erectile dysfunction now have a permanent home in federal device regulation, and with it a fixed list of tests a manufacturer must pass before selling one in the United States.
The Food and Drug Administration published a final order placing the "non-medicated topical formulation for treatment of erectile dysfunction" into class II with special controls, effective July 27. The order adds a new section, 21 CFR 876.5021, to the code that governs gastroenterology and urology devices.
For the roughly 30 million American men affected by ED, according to the National Institute of Diabetes and Digestive and Kidney Diseases, the practical significance is not a new product on shelves. It is that the rules for the next several products are now written down, public, and enforceable.
What "Non-Medicated" Actually Means Here
The phrase is regulatory, not marketing. FDA defines this device type as a formulation applied to the penis that stimulates nerve endings by inducing a temperature change, leading to tumescence and erection.
That definition is the whole point. A product that works by delivering a drug into the bloodstream, as sildenafil does, is reviewed as a drug. A product that works through a physical mechanism, in this case rapid evaporation producing a cooling-then-warming effect, is reviewed as a device. The distinction determines which review pathway applies, what evidence the manufacturer must submit, and how quickly a competitor can follow.
The classification traces back to a request the agency received from Futura Medical Developments Limited in October 2022 for the Eroxon gel. FDA granted the De Novo classification on June 9, 2023. Codifying it in the Code of Federal Regulations took until now, roughly three years, and the order itself notes the classification was applicable on the earlier date.
The Four Risks FDA Named and the Evidence It Requires
The agency identified four health risks for this device type and paired each with a required mitigation. That table is the substance of the rule.
The first risk is that a man uses the product for the wrong condition, which FDA addresses through labeling. The second is a deleterious effect on condoms leading to pregnancy or transmission of sexually transmitted infections, addressed through non-clinical performance testing, labeling, and shelf life testing. The third is adverse tissue reaction, addressed through biocompatibility evaluation. The fourth is pain or discomfort.
To fall inside the classification, a product must be demonstrated biocompatible, must pass non-clinical performance testing covering condom compatibility, temperature profile evaluation and verification of device specifications, and must show performance data supporting its shelf life. Labeling must carry condom compatibility information, an expiration date, an explicit statement that the product is not a contraceptive, information for the correct diagnosis of erectile dysfunction, and dosage and frequency of use.
FDA said class II placement "will provide a reasonable assurance of safety and effectiveness" for this device type, and added that the lower classification reduces regulatory burden compared with the automatic class III assignment that applies to novel devices by default.
One detail deserves emphasis because it is easy to misread. None of the special controls requires a new clinical efficacy trial. They are laboratory and labeling requirements. A company that wants to market a substantially equivalent gel can now use the 510(k) premarket notification route rather than running its own De Novo request, and FDA confirmed it has not exempted this device type from 510(k) requirements.
Why the Condom Clause Is the Most Consequential Line
Of everything in the order, the condom compatibility requirement carries the most direct household consequence.
These gels are applied to the head of the penis immediately before sex. Many of the men and couples using them also rely on condoms for contraception or infection prevention. A formulation that degrades latex would create a failure mode with no warning attached, and the resulting pregnancy or infection would never be traced back to the gel.
By making compatibility testing a condition of the classification and requiring that the finding appear on the label, FDA moved that question out of the manufacturer's discretion. The requirement that labeling state the product is not a contraceptive addresses a separate confusion, since a gel applied at the same moment and in the same place as a spermicide invites the wrong assumption.
What an Over-the-Counter Label Does Not Tell You
The larger clinical concern with self-treating ED is not the gel. It is what the gel may cover up.
Erectile dysfunction is frequently the first visible sign of vascular disease, because the small arteries supplying the penis narrow before the larger coronary arteries do. Aram Loeb, MD, a urologist at University Hospitals, has described ED as a "canary in the coal mine for more significant cardiovascular disease". The Princeton IV consensus recommendations summarized by Mayo Clinic urge clinicians to treat ED as a cardiovascular risk marker, particularly in younger men.
Men most likely to have an underlying cause worth finding include those with diabetes, high blood pressure, high cholesterol, obesity, a smoking history, or a family history of early heart disease, and men whose symptoms began suddenly or progressed quickly. Younger men are not exempt.
A product bought without a prescription skips the conversation that would surface any of this. That is not an argument against the category. It is an argument for treating persistent ED as a reason to see a clinician even when a nonprescription option is working. Anyone with chest pain, shortness of breath on exertion, or a prolonged or painful erection lasting more than four hours needs urgent medical evaluation rather than a retail solution.
What Happens Next
Comments on the classification are closed, and the order is in effect. The next visible development will be 510(k) clearances for competing products, which will appear in FDA's device databases as they are granted and which will now be judged against the specific controls in section 876.5021. FDA's device center posts new orders and guidance on a rolling basis.
A class II category with defined special controls now exists in federal regulation for non-medicated topical ED products. The people most affected are men considering a nonprescription option and their partners. The most reasonable step is to read the label for condom compatibility and the contraception statement, and to raise persistent symptoms with a clinician rather than managing them privately. The central uncertainty is how many products will enter through the newly opened 510(k) door, and how closely their labeling will track what the rule now demands.
Frequently Asked Questions
What did the FDA actually do? It published a final order classifying non-medicated topical erectile dysfunction formulations as class II devices with special controls, and wrote that classification into the Code of Federal Regulations at section 876.5021.
Is this a new product approval? No. It codifies a classification FDA granted in June 2023 for a specific gel. The practical effect is that the standards are now fixed for any product of this type.
Why is a gel regulated as a device and not a drug? Because the defined mechanism is a physical temperature change that stimulates nerve endings, rather than a drug absorbed into the body.
Does this mean these gels are proven to work? The special controls are laboratory and labeling requirements. They do not require a new efficacy trial for follow-on products, which will instead be judged against a cleared predicate.
Can these products damage condoms? FDA identified that as a named risk. Manufacturers must test for condom compatibility and state the result on the label. Read that section before combining a gel with condom use.
Should I see a doctor if a nonprescription option works? Yes, if symptoms persist. Erectile dysfunction often precedes diagnosed cardiovascular disease, and an evaluation can identify treatable causes. This article is general information and not a diagnosis.
When is ED an emergency? An erection lasting more than four hours, severe penile pain, or chest pain and shortness of breath during activity require urgent medical care.
